The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study
Open accessAbstract
Objective To examine clinical effectiveness and safety of apixaban 2.5 mg, dabigatran 110 mg, and rivaroxaban 15 mg compared with warfarin among patients with atrial fibrillation who had not previously taken an oral anticoagulant. Design Propensity weighted (inverse probability of treatment weighted) nationwide cohort study. Setting Individual linked data from three nationwide registries in Denmark. Participants Patients with non-valvular atrial fibrillation filling a first prescription for an oral anticoagulant from August 2011 to February 2016. Patients who filled a prescription for a standard dose non-vitamin K antagonist oral anticoagulant (novel oral anticoagulants, NOACs) were excluded. To control for baseline differences in the population, a propensity score for receipt of either of the four treatment alternatives was calculated to apply an inverse probability treatment weight. Intervention Initiated anticoagulant treatment (dabigatran 110 mg, rivaroxaban 15 mg, apixaban 2.5 mg, and warfarin). Main outcome measures Patients were followed in the registries from onset of treatment for the primary effectiveness outcome of ischaemic stroke/systemic embolism and for the principal safety outcome of any bleeding events. Results Among 55 644 patients with atrial fibrillation who met inclusion criteria, the cohort was distributed according to treatment: apixaban n=4400; dabigatran n=8875; rivaroxaban n=3476; warfarin n=38 893. The overall mean age was 73.9 (SD 12.7), ranging from a mean of 71.0 (warfarin) to 83.9 (apixaban). During one year of follow-up, apixaban was associated with higher (weighted) event rate of ischaemic stroke/systemic embolism (4.8%), while dabigatran, rivaroxaban, and warfarin had event rates of 3.3%, 3.5%, and 3.7%, respectively. In the comparison between a non-vitamin K antagonist oral anticoagulant and warfarin in the inverse probability of treatment weighted analyses and investigation of the effectiveness outcome, the hazard ratios were 1.19 (95% confidence interval 0.95 to 1.49) for apixaban, 0.89 (0.77 to 1.03) for dabigatran, and 0.89 (0.69 to 1.16) for rivaroxaban. For the principal safety outcome versus warfarin, the hazard ratios were 0.96 (0.73 to 1.27) for apixaban, 0.80 (0.70 to 0.92) for dabigatran, and 1.06 (0.87 to 1.29) for rivaroxaban. Conclusion In this propensity weighted nationwide study of reduced dose non-vitamin K antagonist oral anticoagulant regimens, apixaban 2.5 mg twice a day was associated with a trend towards higher rates of ischaemic stroke/systemic embolism compared with warfarin, while rivaroxaban 15 mg once a day and dabigatran 110 mg twice a day showed a trend towards lower thromboembolic rates. The results were not significantly different. Rates of bleeding (the principal safety outcome) were significantly lower for dabigatran, but not significantly different for apixaban and rivaroxaban compared with warfarin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,115
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · Europace · doi:10.1093/europace/euw295 · Cited by 6,439
Self-citation2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw210 · Cited by 6,418
Self-citationMarginal Structural Models and Causal Inference in Epidemiology
Robins, J. M., Hernán, M. Á., & Brumback, B. (2000) · Epidemiology · doi:10.1097/00001648-200009000-00011 · Cited by 5,581
Ruff, C. T., Giugliano, R. P., Braunwald, E., Hoffman, E. B., Deenadayalu, N., Ezekowitz, M. D., Camm, A. J., Weitz, J. I., Lewis, B. S., Parkhomenko, A., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62343-0 · Cited by 5,051
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793
The Danish National Patient Registry: a review of content, data quality, and research potential
Schmidt, M., Schmidt, S. A. J., Sandegaard, J. L., Ehrenstein, V., Pedersen, L., & Sørensen, H. T. (2015) · Clinical Epidemiology · doi:10.2147/clep.s91125 · Cited by 4,769
Pisters, R., Lane, D. A., Nieuwlaat, R., de Vos, C. B., Crijns, H. J. G. M., & Lip, G. Y. H. (2010) · Chest · doi:10.1378/chest.10-0134 · Cited by 4,505
Self-citationAustin, P. C., & Stuart, E. A. (2015) · Statistics in Medicine · doi:10.1002/sim.6607 · Cited by 4,495
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Lip, G. Y. H., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P., ESC Committee for Practice Guidelines (CPG), et al. (2012) · EP Europace · doi:10.1093/europace/eus305 · Cited by 3,822
Self-citation2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.022 · Cited by 2,955
(2013) · Gastroenterology Research · doi:10.1053/j · Cited by 2,759
Gooley, T. A., Leisenring, W., Crowley, J., & Storer, B. E. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o · Cited by 2,688
A tutorial on propensity score estimation for multiple treatments using generalized boosted models
McCaffrey, D. F., Griffin, B. A., Almirall, D., Slaughter, M. E., Ramchand, R., & Burgette, L. F. (2013) · Statistics in Medicine · doi:10.1002/sim.5753 · Cited by 1,450
Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H.-C., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., & Kirchhof, P. (2015) · Europace · doi:10.1093/europace/euv309 · Cited by 1,113
Stroke and bleeding in atrial fibrillation with chronic kidney disease
Olesen, J. B., Lip, G. Y. H., Kamper, A.-L., Hommel, K., Køber, L., Lane, D. A., Lindhardsen, J., Gislason, G. H., & Torp-Pedersen, C. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105594 · Cited by 930
Self-citationAustin, P. C. (2009) · Biometrical Journal · doi:10.1002/bimj.200810488 · Cited by 769
Two Novel Equations to Estimate Kidney Function in Persons Aged 70 Years or Older
Schaeffner, E. S., Ebert, N., Delanaye, P., Frei, U., Gaedeke, J., Jakob, O., Kuhlmann, M. K., Schuchardt, M., Tölle, M., Ziebig, R., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-7-201210020-00003 · Cited by 632
Diagnosing and responding to violations in the positivity assumption
Petersen, M. L., Porter, K. E., Gruber, S., Wang, Y., & van der Laan, M. J. (2012) · Statistical Methods in Medical Research · doi:10.1177/0962280210386207 · Cited by 548
Larsen, T. B., Skjøth, F., Nielsen, P. B., Kjældgaard, J. N., & Lip, G. Y. H. (2016) · BMJ · doi:10.1136/bmj.i3189 · Cited by 441
Self-citationLarsen, T. B., Rasmussen, L. H., Skjøth, F., Due, K. M., Callréus, T., Rosenzweig, M., & Lip, G. Y. H. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.03.020 · Cited by 403
Self-citationHijazi, Z., Hohnloser, S. H., Oldgren, J., Andersson, U., Connolly, S. J., Eikelboom, J. W., Ezekowitz, M. D., Reilly, P. A., Siegbahn, A., Yusuf, S., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.003628 · Cited by 396
Halvorsen, S., Atar, D., Yang, H., De Caterina, R., Erol, C., Garcia, D., Granger, C. B., Hanna, M., Held, C., Husted, S., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu046 · Cited by 370
Validity of Stroke Diagnoses in a National Register of Patients
Krarup, L.-H., Boysen, G., Janjua, H., Prescott, E., & Truelsen, T. (2007) · Neuroepidemiology · doi:10.1159/000102143 · Cited by 366
Stroke Prevention in Atrial Fibrillation: A Systematic Review
Lip, G. Y. H., & Lane, D. A. (2015) · JAMA · doi:10.1001/jama.2015.4369 · Cited by 322
Self-citationStürmer, T., Wyss, R., Glynn, R. J., & Brookhart, M. A. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12197 · Cited by 302
Glassock, R. J., & Rule, A. D. (2012) · Kidney International · doi:10.1038/ki.2012.65 · Cited by 292
Frost, C., Nepal, S., Wang, J., Schuster, A., Byon, W., Boyd, R. A., Yu, Z., Shenker, A., Barrett, Y. C., Mosqueda‐Garcia, R., et al. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12106 · Cited by 286
Schneeweiss, S., Gagne, J. J., Glynn, R. J., Ruhl, M., & Rassen, J. A. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.235 · Cited by 192
Hijazi, Z., Hohnloser, S. H., Andersson, U., Alexander, J. H., Hanna, M., Keltai, M., Parkhomenko, A., López-Sendón, J. L., Lopes, R. D., Siegbahn, A., et al. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.1170 · Cited by 173
Diener, H., Aisenberg, J., Ansell, J., Atar, D., BREITHARDT, G. E., Eikelboom, J. W., Ezekowitz, M. D., Granger, C. B., Halperin, J. L., Hohnloser, S. H., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw069 · Cited by 145
Self-citationValidation of CKD and Related Conditions in Existing Data Sets: A Systematic Review
Grams, M. E., Plantinga, L., Hedgeman, E., Saran, R., Myers, G. L., Williams, D. E., & Powe, N. R. (2010) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2010.05.013 · Cited by 140
Evaluation of patients’ attitudes towards stroke prevention and bleeding risk in atrial fibrillation
Regpala, S., Lacombe, S., Sharma, M., Gibbens, S., Ball, D., Francis, K., & LaHaye, S. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-05-0424 · Cited by 130
Stürmer, T., Rothman, K. J., & Glynn, R. J. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1231 · Cited by 121
Comparisons between Novel Oral Anticoagulants and Vitamin K Antagonists in Patients with CKD
Harel, Z., Sholzberg, M., Shah, P. S., Pavenski, K., Harel, S., Wald, R., Bell, C. M., & Perl, J. M. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013040361 · Cited by 108
Clemens, A., Noack, H., Ferreira, J., Connolly, S. J., Yusuf, S., & Lip, G. Y. H. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-09-0734 · Cited by 106
Self-citationNielsen, P. B., Lane, D. A., Rasmussen, L. H., Lip, G. Y. H., & Larsen, T. B. (2014) · Clinical Research in Cardiology · doi:10.1007/s00392-014-0797-9 · Cited by 98
Self-citationDabigatran use in elderly patients with atrial fibrillation
Avgil-Tsadok, M., Jackevicius, C. A., Essebag, V., Eisenberg, M. J., Rahme, E., Behlouli, H., & Pilote, L. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-03-0247 · Cited by 95
Gorst‐Rasmussen, A., Lip, G. Y. H., & Larsen, T. B. (2016) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4034 · Cited by 85
Self-citationLip, G. Y. H., & Lane, D. A. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-01-0063 · Cited by 70
Self-citation
Cited by
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström-Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., Dilaveris, P. E., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa612 · Cited by 9,971
Self-citationSteffel, J., Verhamme, P., Potpara, T. S., Albaladejo, P., Antz, M., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy136 · Cited by 2,123
Self-citationSiontis, K. C., Zhang, X., Eckard, A., Bhave, N., Schaubel, D. E., He, K., Tilea, A., Stack, A. G., Balkrishnan, R., Yao, X., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.035418 · Cited by 492
Yao, X., Shah, N. D., Sangaralingham, L. R., Gersh, B. J., & Noseworthy, P. A. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.03.600 · Cited by 467
Vinogradova, Y., Coupland, C., Hill, T., & Hippisley-Cox, J. (2018) · BMJ · doi:10.1136/bmj.k2505 · Cited by 275
Metadata
- Authors
- Nielsen, P. B., Skjøth, F., Søgaard, M., Kjældgaard, J. N., Lip, G. Y. H., & Larsen, T. B.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2017-02-10
- Volume
- 356
- Pages
- j510
- ISSN
- 1756-1833 (ISSN-L)
- 0959-8138
- OpenAlex
- W2587045166
- Cited by
- 346
- References
- 43
- FWCI
- 38.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.